COLUMBUS, Ohio, Sept. 13, 2017 /PRNewswire/ -- Researchers from
Invitae Corporation (NYSE: NVTA), one of the fastest growing
genetic information companies, will present initial findings
showing proactive genetic health screening revealed medically
significant findings for nearly one in five patients in a study
presented at the National Society of Genetic Counselors (NSGC) 36th
Annual Conference. The company will also unveil a new software
platform to help genetic counselors gather and manage family
history and patient information essential for clinical decision
making. The information is among the wide-ranging research and
expanded services being featured at the meeting.
Increasingly, healthy individuals are seeking genetic testing to
identify their personal risks for inherited conditions such as
cancer. Data presented at NSGC highlights the potential importance
of these tests for planning health screenings. A retrospective
analysis of 120 patients tested with a genetic screening panel for
healthy adults found pathogenic or likely pathogenic results in 18
percent of patients, predominantly in genes associated with an
elevated risk for cancer or cardiovascular disease. Invitae
currently has a number of proactive genetic testing programs
underway using this type of proactive genetic screening in primary
care settings.
"Interest among otherwise healthy adults in using genetic
information to understand their risk of disease continues to grow
each year. These and other data show that interest is well-placed,
with a substantial group of patients showing genetic variants
associated with elevated risk of diseases like cancer where
monitoring and early intervention can be helpful," said
Robert Nussbaum, M.D., chief medical
officer of Invitae. "Use of genetic screening in the primary care
setting can assess risk to help shape individual screening plans.
We are continually adding tools and resources that help reduce
barriers to the widespread use of genetic information in mainstream
medical practice."
Expanded support for understanding families' genetic
information
Making health decisions based on genetic test results, family
history and clinical information requires genetic counselors to
assemble and analyze a significant amount of information. A new
version of CancerGene Connect, the award-winning risk assessment
and family history tool, is being made available at no charge to
provide a software solution that simplifies data gathering,
tracking and analysis for all genetic counselors and their
patients, regardless of whether they order testing from Invitae or
not. Designed by clinicians, the new tool automates family history
information gathering and provides genetic counselors and other
clinicians with a suite of analysis tools to improve their ability
to care for patients. CancerGene Connect became part of Invitae in
June 2017.
"The combination of genetic information and family health
history is important for understanding health risks within cancer
and a growing list of cardiovascular, metabolic, neurological and
other conditions. Gathering, organizing and analyzing the spectrum
of relevant clinical information patient-by-patient can be
extremely time consuming for genetic counselors," said Dr.
Nussbaum. "CancerGene Connect cuts down on the time needed for data
gathering and analysis so genetic counselors can spend their time
working directly with patients and clinicians to understand the
results."
Full research presentation schedule
The full schedule of the Invitae researchers' presentations at
the meeting is as follows:
Wednesday, September
13:
- Poster #A-1: Using characteristics of industry genetic
counselors to inform ongoing workforce discussions | Presented by
Chris Tan, MS, LCGC, Invitae |
5:15 pm ET.
- Poster #A-25: Utilization and findings of a rapid turnaround
lab process for hereditary breast cancer | Presented by
Kimberly King-Spohn, MS, CGC,
WellStar Center for Genetics and Cancer Screening Services |
5:15 pm ET.
- Poster #A-82: The paperwork matters! The importance of clinical
phenotype information in variant interpretation | Presented by
Michael J. Anderson, PhD, Invitae |
5:15 pm ET.
- Poster #A-115: Developing genetic education to improve
postmortem genetics - the NSGC Postmortem Working Group (PMWG)
Collaborative Experience | Presented by Heather McLeod, MS, CGC, Sudden Death in the
Young (SDY) Registry | 5:15 pm
ET.
- Poster #A-136: The impact of preconception AGG interruption
testing on fragile X syndrome carriers in the fertility setting |
Presented by Julia Wilkinson, MS,
LCGC, Good Start Genetics | 5:15 pm
ET.
Thursday, September 14:
- Poster #B-53: A retrospective analysis of preliminary results
from a medically actionable genetic screening panel for healthy
individuals | Presented by Eden
Haverfield, PhD, FACMG, Invitae | 5:45 pm ET.
- Poster #B-104: Agreement and disagreement among variant
classification in ClinVar: Critical factors clinicians should know
| Presented by Stephen E. Lincoln,
Invitae | 5:45 pm ET.
Friday, September 15:
- Presentation #1030: High-depth multi-gene panel analysis with
integrated sequence and copy number detection is a useful
first-tier test with a high diagnostic yield and broad mutation
spectrum detection in childhood epilepsy | Presented by
Darlene Riethmaier, MS, CGC, Invitae
| 12:15 pm ET.
- Presentation #1232: Addition of a remote genetic counselor to
the breast specialist's team improves clinical decision-making |
Presented by Erin O'Leary, MS, CGC,
Invitae | 3:45 pm ET.
- Poster #C-114: Next-generation sequencing and a novel
bioinformatic approach identifies copy number variation in ion
channel genes in a clinical laboratory | Presented by Emily James, MS, LCGC, Invitae | 1:15 pm ET.
- Poster #C-129: Counseling healthy individuals for preventive
genetic screening: A case report | Presented by Sienna Aguilar, MS,
CGC, Invitae | 1:15 pm ET.
- Poster #C-204: Identification of balanced translocation
carriers through routine preimplantation genetic screening |
Presented by Dana K. Neitzel, MS,
CGC, Good Start Genetics | 1:15 pm
ET.
- Poster #C-288: Diagnostic yield for neurological and
neuromuscular disorders testing with high-depth multi-gene panel
analysis with integrated sequence and copy number detection |
Presented by Darlene Riethmaier, MS,
CGC, Invitae | 1:15 pm ET.
Saturday, September 16:
- Presentation #1216: Targeted cascade testing: Are we missing
the forest for the trees? | Presented by Scott Michalski, MS, LCGC, Invitae |
12:00 pm ET.
- Presentation #1275: Beyond BRCA: Germline genetic testing in
prostate cancer, do we need disease-specific guidelines | Presented
by Ian Wilson, PhD, FACMG, Invitae |
12:30 pm ET.
For more information on Invitae's presence at NSGC, please visit
www.invitae.com/nsgc2017. Additional information on the NSGC Annual
Conference is also available at www.nsgc.org/conference.
About Invitae
Invitae Corporation (NYSE: NVTA) is one
of the fastest growing genetic information companies in
the United States. Invitae
Corporation's mission is to bring comprehensive genetic information
into mainstream medical practice to improve the quality of
healthcare for billions of people. Invitae's goal is to aggregate
the world's genetic tests into a single service with higher
quality, faster turnaround time, and lower prices. For more
information, visit our website at invitae.com.
Safe Harbor Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
relating to research that highlights the utility of proactive
genetic screening in healthy adults; that the company is
continually adding tools and resources that help reduce barriers to
the widespread use of genetic information in mainstream medical
practice; and the benefits of CancerGene Connect. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially, and reported results should
not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to:
risks associated with the company's ability to use rapidly changing
genetic data to interpret test results accurately and consistently;
laws and regulations applicable to the company's business; the
company's limited experience with respect to acquisitions and its
ability to integrate newly acquired companies successfully into its
existing business; security breaches, loss of data and other
disruptions; the company's history of losses; the company's ability
to compete; and the other risks set forth in the company's filings
with the Securities and Exchange Commission, including the risks
set forth in the company's Quarterly Report on Form 10-Q for the
quarter ended June 30, 2017. These
forward-looking statements speak only as of the date hereof, and
Invitae Corporation disclaims any obligation to update these
forward-looking statements.
NOTE: Invitae and the Invitae logo are trademarks of Invitae
Corporation. All other trademarks and service marks are the
property of their respective owners.
Contact:
Laura D'Angelo
pr@invitae.com
314-920-0617
View original content with
multimedia:http://www.prnewswire.com/news-releases/invitae-highlighting-new-research-expanded-suite-of-services-at-national-society-of-genetic-counselors-nsgc-36th-annual-conference-300518457.html
SOURCE Invitae Corporation